Therapeutic drug monitoring opportunities in cancer therapy

Pharmacology and Therapeutics

Volumn 74, Issue 1, 1997, Pages 39-54

  McLeod, Howard L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cancer chemotherapy; Cancer therapeutics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CARBOPLATIN; ETOPOSIDE; FLUOROURACIL; MERCAPTOPURINE; METHOTREXATE;

AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0030749434     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(96)00201-X     Document Type: Review

References (94)

1. Au, J. L.-S., Rustum, Y. M., Ledesma, E. J., Mittelman, A. and Creaven, P. J. (1982) Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res. 42: 2930-2937.
2. Barberi-Heyob, M., Weber, B., Merlin, J. L., Dittrich, C., de Bruijn, E. A., Luporsi, E. and Guillemin, F. (1995) Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. Cancer Chemother. Pharmacol. 37: 110-116.
3. Bennett, C. L., Sinkule, J. A., Schilsky, R. L., Senekjian, E. and Choi, K. E. (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 47: 1952-1956.
4. Blommaert, F. A., Michael, C., Terheggen, P. M. A. B., Muggia, F. M., Kortes, V., Schornagel, J. H., Hart, A. A. M. and den Engelse, L. (1993) Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res. 53: 5669-5675.
5. Borsi, J. D. and Moe, P. J. (1987) Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 60: 3020-3024.
6. Bruno, R., Vivier, N., Vergniol, J. C., De Phillips, S. L., Montay, G. and Sheiner, L. B. (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm. 24: 153-172.
7. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E. and Wiltshaw, E. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-1756.
8. Camitta, B., Mahoney, D., Leventhal, B., Lauer, S. J., Shuster, J. J., Adair, S., Civin, C., Munoz, L., Steuber, P., Strother, D. and Kamen, B. A. (1994) Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J. Clin. Oncol. 12: 1383-1389.
9. Chatelut, E., Canal, P., Brunner, V., Chevreau, C., Pujol, A., Boneu, A., Roche, H., Houin, G. and Bugat, R. (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst. 87: 573-580.
10. Chatelut, E., Boddy, A. V., Peng, B., Rubie, H., Lavit, M., Dezeuze, A., Pearson, A. D. J., Roche, H., Robert, A., Newell, D. R. and Canal, P. (1996) Population pharmacokinetics of carboplatin in children. Clin. Pharmacol. Ther. 59: 436-443.
11. Childs, W. J., Nicholls, E. J. and Horwich, A. (1992) The optimisation of carboplatin dose in carboplatin, etoposide, and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann. Oncol. 3: 291-296.
12. Clark, P. I. and Slevin, M. L. (1987) The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12: 223-252.
13. Crom, W. R. and Evans, W. E. (1992) Methotrexate, In: Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Ch. 29, pp. 1-42, Evans, W. E., Schentag, J. J. and Jusko, W. J. (eds.) Applied Therapeutics, Inc., Spokane.
14. Desoize, B. and Robert, J. (1994) Individual dose adaptation of anticancer drugs. Eur. J. Cancer 30A: 844-851.
15. Desoize, B., Marechal, F. and Cattan, A. (1990) Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. Br. J. Cancer 62: 840-841.
16. Egorin, M. J., Van Echo, D. A., Olman, E. A., Whitacre, M. Y., Forrest, A. and Aisner, J. (1985) Prospective validation of a pharmacologically based dosing scheme for the cis-diamminidichloroplatinum (II) analogue diamminiecyclobutanedicarboxylatoplatinum. Cancer Res. 45: 6502-6506.
17. Evans, W. E., Crom, W. R., Stewart, C. F., Bowman, W. P., Chen, C. H., Abromowitch, M. and Simone, J. V. (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia. Lancet i: 359-362.
18. Evans, W. E., Crom, W. R., Abromowitch, M., Dodge, R., Look, A. T., Bowman, W. P., George, S. L. and Pui, C.-H. (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314: 471-477.
19. Evans, W. E., Schell, M. J. and Pui, C.-H. (1990) MTX clearance is more important for intermediate-risk ALL. J. Clin. Oncol. 8: 1115.
20. Evans, W. E., Horner, M. H., Chu, Y. Q., Kalwinsky, D. and Roberts, W. M. (1991a) Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119: 985-989.
21. Evans, W. E., Rodman, J., Relling, M. V., Crom, W. R., Rivera, G. K., Crist, W. M. and Pui, C-H. (1991b) Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin. Hemat. 28 (Suppl. 4): 15-21.
22. Fety, R., Rolland, F., Barberi-Heyob, M., Merlin, J.-L., Conroy, T., Hardouin, A., Riviere, A. and Milano, G. (1994) Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res. 14: 2347-2352.
23. Fleming, R. A., Milano, G. A., Thyss, A., Etienne, M.-C., Renee, N., Schneider, M. and Demard, F. (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52: 2899-2902.
24. Fleming, R. A., Milano, G. A., Gaspard, M. H., Bargnoux, P. J., Thyss, A., Plagne, R., Renee, N., Schneider, M. and Demard, F. (1993) Dihydropyrimidine dehydrogenase activity in cancer patients. Eur. J. Cancer 29A: 740-744.
25. Fry, A. M., Chresta, C. M., Davies, S. M., Walker, M. C., Harris, A. L., Hartley, J. A., Masters, J. R. W. and Hickson, I. D. (1991) Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51: 6592-6595.
26. Galpin, A. J. and Evans, W. E. (1993) Therapeutic drug monitoring in cancer management. Clin. Chem. 39: 2419-2430.
27. Gamelin, E. C., Danquechin-Dorval, E. M., Dumesnil, Y. F., Maillart, P. J., Goudier, M. J., Burtin, P. C., Delva, R. G., Lortholary, A. H., Gesta, P. H. and Larra, F. G. (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-445.
28. Graf, N., Winkler, K., Betlemovic, M., Fuchs, N. and Bode, U. (1994) Methotrexate pharmacokinetics and prognosis in osteosarcoma. J. Clin. Oncol. 12: 1443-1451.
29. Harris, B. E., Carpenter, J. T. and Diasio, R. B. (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68: 499-501.
30. Hayder, S., Lafolie, P., Bjork, O. and Peterson, C. (1989) 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther. Drug Monit. 11: 617-622.
31. Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughts, J. N., Goodlow, J. L., Tan, S. and Wiltshaw, E. (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol. 10: 520-528.
32. Joel, S. P., Shah, R. and Slevin, M. L. (1994) Etoposide dosage and pharmacodynamics. Cancer Chemother. Pharmacol. 34: S69-S75.
33. Jones, A., Wiltshaw, E., Harper, P., Sleven, M., Shepherd, J., Mansi, J., Blake, P., Tan, S. and Gore, M. (1992) A randomised study of high versus conventional dose carboplatin for previously untreated ovarian cancer. Br. J. Cancer 65 (Suppl. 16): 15.
34. Karlsson, M. O., Port, R. E., Ratain, M. J. and Sheiner, L. B. (1995) A population model for the leukopenic effect of etoposide. Clin. Pharmacol. Ther. 57: 325-334.
35. Koren, G., Ferrazini, G., Sulh, H., Langevin, A. M., Kapelushnik, J., Klein, J., Giesbrect, E., Soldin, S. and Greenberg, M. (1990) Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N. Engl. J. Med. 323: 17-21.
36. Kunitoh, H. and Watanabe, K. (1994) Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 12: 83-89.
37. Laufman, L. R., Bukowski, R. M., Collier, M. A., Sullivan, B. A., McKinnis, R. A., Clendennin, N. J., Guaspari, A. and Brenckman, W. D., Jr. (1993) A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 11: 1888-1893.
38. Lennard, L. (1992) The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43: 329-339.
39. Lennard, L. and Lilleyman, J.S. (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 7: 1816-1823.
40. Lennard, L., Lilleyman, J. S., Van Loon, J. A. and Weinshilboum, R. M. (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229.
41. Lennard, L., Welch, J. and Lilleyman, J.S. (1995) Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br. J. Cancer 72: 1004-1006.
42. Lilleyman, J. S. and Lennard, L. (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343: 1188-1190.
43. Lilliemark, E. K., Lilliemark, J., Pettersson, B., Gruber, A., Bjorkholm, M. and Peterson, C. (1993) In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. Leuk. Lymphoma 10: 323-328.
44. Lu, Z.-H., Zhang, R. and Diasio, R. B. (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy. Cancer Res. 53: 5433-5438.
45. Mahmoud, H., Relling, M., Crist, W., Rivera, G., Boyett, J., Krance, R., Ribeiro, R., Furman, W., Sandlund, T., Evans, W. and Pui, C.-H. (1993) Retrieval therapy including daily oral etoposide for children with relapsed acute lymphoblastic leukemia. Proc. Am. Soc. Clin. Oncol. 12: 316.
46. Marina, N. M., Rodman, J. H., Shema, S. J., Bowman, L. C., Douglass, E., Furman, W., Santana, V. M., Hudson, M., Wilimas, J., Meyer, W. H., Madden, T. and Pratt, C. B. (1993) Phase-1 study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J. Clin. Oncol. 11: 554-560.
47. McLeod, H. L. and Evans, W. E. (1993) Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv. 17: 253-268.
48. McLeod, H. L. and Evans, W. E. (1995) Clinical pharmacodynamics of anticancer drugs. In: Handbook of Pharmacokinetic/Pharmacodynamic Correlation, pp. 389-413, Derendorf, H. and Hochaus, G. (eds.) CRC Press, Boca Raton.
49. McLeod, H. L., Miller, D. R. and Evans, W. E. (1993) Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341: 1151.
50. McLeod, H. L., Douglas, F., Oates, M., Symonds, R. P., Prakash, D., van der Zee, A. G. J., Kaye, S. B., Brown, R. and Keith, W. N. (1994) Topoisomerase I and II activity in human breast, cervix, lung, and colon cancer. Int. J. Cancer 59: 607-611.
51. McLeod, H. L., Relling, M. V., Liu, Q., Pui, C.-H. and Evans, W. E. (1995) Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85: 1897-1902.
52. McMurrough, J. and McLeod, H. L. (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br. J. Clin. Pharmacol. 41: 425-427.
53. Mick, R. and Ratain, M. J. (1991) Modelling interpatient pharmacodynamic variability of etoposide. J. Natl. Cancer Inst. 83: 1560-1564.
54. Milano, G., Roman, P., Khater, R., Frenay, M., Renee, N. and Namer, M. (1988) Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int. J. Cancer 41: 537-541.
55. Milano, G., Etienne, M.-C., Cassuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M. and Demard, F. (1992) Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. 10: 1171-1175.
56. Milano, G., Etienne, M.-C., Renee, N., Thyss, A., Schneider, M., Raimaioli, A. and Demard, F. (1994) Relationship between fluorouracil systemic exposure and tumour response and patient survival. J. Clin. Oncol. 12: 1291-1295.
57. Miller, A. A. and Tolley, E. A. (1994) Predictive performance of a pharmacodynamic model for oral etoposide. Cancer Res. 54: 2080-2083.
58. Miller, A. A., Stewart, C. F. and Tolley, E. A. (1990) Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother. Pharmacol. 25: 361-366.
59. Miller, A. A., Tolley, E. A., Niell, H. B., Stewart, C. F. and Griffin, J. P. (1992) Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother. Pharmacol. 31: 161-166.
60. Miller, A. A., Tolley, E. A., Niell, H. B., Griffin, J. P. and Mauer, A. M. (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 11: 1179-1188.
61. Minami, H., Shimokata, K., Saka, H., Saito, H., Ando, Y., Senda, K., Nomura, F. and Sakai, S. (1993) Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J. Clin. Oncol. 11: 1602-1608.
62. Minami, H., Ando, Y., Sakai, S. and Shimokata, K. (1995) Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J. Clin. Oncol. 13: 191-199.
63. Newell, D. R. (1994) Pharmacokinetic monitoring of novel topoisomerase I inhibitors and tubulin binding agents in phase II clinical trials. Ann. Oncol. 5 (Suppl. 5): 164.
64. Newell, D. R., Pearson, A. D. J., Balmanno, K., Price, L., Wyllie, R. A., Keir, M., Calvert, A. H., Lewis, I. J., Pinkerton, C. R. and Stevens, M. C. G. (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J. Clin. Oncol. 11: 2314-2323.
65. Peters, G. J. and van Groeningen, C. J. (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2: 469-480.
66. Pinkerton, C. R., Dick, G. and Aherne, G. W. (1993) 24-Hour plasma etoposide profile after oral and intravenous administration in children. Eur. J. Cancer 29A: 1479-1481.
67. Presant, C. A., Wolf, W., Waluch, V., Wiseman, C., Kennedy, P., Blayney, D. and Brechner, R. R. (1994) Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343: 1184-1187.
68. Ratain, M. J., Schilsky, R. L., Conley, B. A. and Egorin, M. J. (1990) Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8: 1739-1753.
69. Ratain, M. J., Mick, R., Schilsky, R. L., Vogelzang, N. J. and Berezin, F. (1991 ) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol. 9: 1480-1486.
70. Reed, E., Parker, R. J., Gill, I., Bicher, A., Dabholkar, M., Vionnet, J. A., Bostick-Bruton, F., Tarone, R. and Muggia, F. M. (1993) Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res. 53: 3694-3699.
71. Relling, M. V., Fairclough, D., Ayers, D., Crom, W. R., Rodman, J. H., Pui, C.-H. and Evans, W. E. (1994a) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J. Clin. Oncol. 12: 1667-1672.
72. Relling, M. V., McLeod, H. L., Bowman, L. C. and Santana, V. M. (1994b) Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther. 56: 503-511.
73. Rodman, J. H., Murry, D. J., Madden, T. and Santana, V. M. (1994) Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J. Clin. Oncol. 12: 2390-2397.
74. Sandstöm, M., Freijs, A., Larsson, R., Nygren, P., Fjällskog, M.-L., Bergh, J. and Karlsson, M. O. (1996) Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 5-hydroxycyclophosphamide regimen in breast cancer patients. J. Clin. Oncol. 14: 1581-1588.
75. Santini, J., Milano, G., Thyss, A., Renee, N., Viens, P., Ayela, P., Schneider, M. and Demard, F. (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer 59: 287-290.
76. Schellens, J. H. M., Ma, J., Planting, A. S. Th., van der Burg, M. E. L., van Meerten, E., de Boer-Dennert, M., Schmitz, P. I. M., Stoter, G. and Verweij, J. (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer 73: 1569-1575.
77. Schmiegelow, K., Schroder, H., Pulczynska, M. K. and Hejl, M. (1989) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother. Pharmacol. 25: 65-69.
78. Schmiegelow, K., Schroder, H., Gustafsson, G., Kristinsson, J., Glomstein, A., Salmi, T. and Wranne, L. (1995) Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J. Clin. Oncol. 13: 345-351.
79. Slevin, M. L., Clark, P. I., Joel, S. P., Malik, S., Osborne, R. J., Gregory, W. M., Lowe, D. G., Reznek, R. H. and Wrigley, P. F. M. (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 7: 1333-1340.
80. Sonnichsen, D. S., Ribeiro, R. C., Luo, X., Mathew, P. and Relling, M. V. (1995) Pharmacokinetics and pharmacodynamics of 21 day continuous oral etoposide in pediatric solid tumor patients. Clin. Pharmacol. Ther. 58: 99-107.
81. Statbite (1995) Cancer and heart disease deaths. J. Natl. Cancer Inst. 87: 1206.
82. Stewart, C. F., Arbuck, S. G., Pieper, J. A. and Evans, W. E. (1989) Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Ther. 45: 49-55.
83. Stewart, C. F., Arbuck, S. G., Fleming, R. A. and Evans, W. E. (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther. 50: 385-393.
84. Stoller, R. G., Hande, K. R., Jacobs, S. A., Rosenberg, S. A. and Chabner, B. A. (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N. Engl. J. Med. 297: 630-634.
85. Synold, T. W., Relling, M. V., Boyett, J. M., Rivera, G. K., Sandlund, J. T., Mahmoud, H., Crist, W. M., Pui, C.-H. and Evans, W. E. (1994) Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 94: 1996-2001.
86. Thyss, A., Milano, G., Renee, N., Valicioni, J., Schneider, M. and Demard, F. (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother. Pharmacol. 16: 64-66.
87. Trump, D. L., Egorin, M. J., Forrest, A., Willson, J. K. V., Remick, S. and Tutsch, K. D. (1991) Pharmacokinetic and pharmacodynatnic analysts of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J. Clin. Oncol. 9: 2027-2035.
88. van der Vijgh, W. J. F. (1991) Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21: 242-261.
89. van Groeningen, C. J., Pinedo, H. M., Heddes, J., Kok, R. M., de Jong, A. P. J. M., Wattel, E., Peters, G. J. and Lankelma, J. (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48: 6956-6961.
90. van Warmerdam, L. J., Rodenhuis, S., ten Bokkel Huinink, W. W., Maes, R. A. and Beijnen, J. H. (1996) Evaluation of formulas using the serum creatinine to calculate the optimal dosage of carboplatin. Cancer Chemother. Pharmacol. 37: 266-270.
91. Warren, D. J., Andersen, A. and Slordal, L. (1995) Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res. 55: 1670-1674.
92. Wei, X. X., McLeod, H. L., McMurrough, J., Gonzalez, F. J. and Fernandez-Salguero, P. (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98: 610-615.
93. Wingo, P. A., Tong, T. and Bolden, S. (1995) Cancer statistics, 1995 CA Cancer J. Clin. 45: 8-30.
94. Yoshida, T., Araki, E., Iigo, M., Fujii, T., Yoshino, M., Shimada, Y., Saito, D., Tajiri, H., Yamaguchi, H., Yoshida, S., Yoshino, M., Ohkura, H., Yoshimori, M. and Okazaki, N. (1990) Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother. Pharmacol. 26: 352-354.